Editor's Note: The 10th West China Tianfu Academic Conference on Urologic Oncology was held in Chengdu from November 5 to 7, 2026. To date, renal cancer still lacks a biomarker comparable to PSA. Diagnosis relies on imaging, while postoperative management depends on follow-up, leaving a critical gap in the framework for precise risk stratification. Against this backdrop, Oncology Frontier – UroStream invited Professor Fufu Zheng from the First Affiliated Hospital of Sun Yat-sen University to share his insights on the most pressing biomarker needs in renal cancer, the clinical value of KIM-1 and ctDNA, how biomarkers can be incorporated into risk-stratified treatment, and the pathway from biomarker discovery to standardized clinical implementation.

01

Oncology Frontier – UroStream

What are the current unmet needs in the diagnosis and treatment of renal cancer?

Professor Fufu Zheng: Biomarkers for renal cancer have long been lacking. This is quite different from prostate cancer, which has PSA—a biomarker that can be used not only for diagnosis but also for postoperative monitoring and surveillance during biochemical recurrence. By contrast, renal cancer still has no diagnostic biomarker. There is currently no blood test that can be used to diagnose renal cancer during routine health examinations, so imaging remains the mainstay of diagnosis. This is precisely why so much research has focused on biomarkers.

At the molecular and genetic levels, however, markers such as PBRM1, SETD2, and VHL cannot yet accurately determine whether renal cancer is present, nor can they reliably predict prognosis or tumor aggressiveness.

What is truly worth focusing on in recent years is research that translates discoveries into practical clinical applications. At this conference, for example, findings from Dana-Farber Cancer Institute at Harvard University were presented, involving molecular biomarkers such as ctDNA and the KIM-1 index. Ultimately, biomarkers are a prerequisite for bringing renal cancer into the era of precision medicine—that is, precision diagnosis and precision treatment.

02

Oncology Frontier – UroStream

Circulating blood-based biomarkers, including kidney injury molecules, are being investigated in renal cancer. How do you view their potential value in assessing postoperative recurrence risk and enabling dynamic monitoring? What challenges still need to be addressed before these biomarkers can move from research into clinical practice?

Professor Fufu Zheng: The kidney injury molecule KIM-1 is currently attracting considerable attention. It has significant potential value in postoperative management, particularly in guiding the use of adjuvant immunotherapy.

However, as a professor from Dana-Farber Cancer Institute at Harvard University pointed out, the testing methods, cutoff values, and criteria for interpreting the KIM-1 index are not yet standardized across different medical centers. Consequently, several important questions remain unanswered: Does an elevated KIM-1 index truly indicate a poorer prognosis or a higher risk of recurrence or metastasis? Does it mean that a patient needs adjuvant therapy or intensified adjuvant treatment, such as pembrolizumab-based adjuvant therapy as used in KEYNOTE-564?

KIM-1 is already being used in some clinical studies. For example, researchers are exploring whether adjuvant therapy should be initiated when postoperative monitoring detects an increase in the index, and whether treatment should be intensified when the index fails to decline during adjuvant therapy. These questions require further investigation.

KIM-1 is, after all, a single biomarker, and its ability to accurately reflect risk still needs to be validated. With the help of artificial intelligence, combining KIM-1 with other molecular biomarkers, such as ctDNA testing and genetic mutations, may enable more accurate prediction of recurrence and metastasis risk. This should be an important direction for future research.

03

Oncology Frontier – UroStream

When assessing risk and selecting treatment for patients with renal cancer, clinicians need to consider disease stage, pathological characteristics, and the patient’s physical condition. In the future, how can biomarkers be integrated with these factors to better support patient stratification and individualized treatment? What questions still need to be addressed through prospective studies?

Professor Fufu Zheng: Precision treatment for renal cancer is an ongoing process: the first step is precision diagnosis, followed by stratification into high-, intermediate-, and low-risk groups, with different treatment approaches assigned to each group.

Risk stratification must take the pathological characteristics of the tumor into account. The management of clear cell renal cell carcinoma differs from that of non-clear cell renal cell carcinoma. Among non-clear cell renal cancers, there are also several subtypes associated with specific genetic alterations, including TFE3 translocation renal cell carcinoma, SMARCB1-associated renal cell carcinoma, and FH-deficient renal cell carcinoma. These tumors are highly aggressive and have poor prognoses, requiring more intensive and targeted treatment based on the corresponding mutations. For patients with VHL mutations, corresponding drugs are already available, such as the HIF-2α inhibitor belzutifan. At the 2026 ESMO Congress, particular attention was also given to intensifying treatment with belzutifan in combination with existing therapeutic agents such as lenvatinib and pembrolizumab.

The patient’s own condition must also be considered. Patients with renal cancer often have comorbidities, including hematological and metabolic disorders. These factors help guide the choice among targeted therapy, targeted therapy combined with immunotherapy, dual-targeted therapy, and dual-immunotherapy combinations. Only through precise risk stratification and individualized treatment can we avoid both overtreatment and undertreatment.

The key question for prospective studies is how to make individualized treatment decisions for each disease state. With the availability of artificial intelligence, we can now incorporate pathological information, the patient’s physical condition, prognostic assessments, and even economic factors into the decision-making process to identify the most appropriate standard treatment for each patient.

04

Oncology Frontier – UroStream

How should collaboration between centers and standardization be advanced in the future to ensure that valuable research findings better serve the long-term management of patients with renal cancer?

Professor Fufu Zheng: Translating basic research findings into clinical applications is currently a major national development priority. The ultimate purpose of basic research is to benefit patients.

Basic research has expanded from genomics to RNA omics, proteomics, and metabolomics, generating enormous volumes of data. Clinical research, meanwhile, spans the entire pathway from innovative drug development to the establishment of standard treatments. The key is to focus research on clinical pain points, challenges, and unmet needs, and to conduct selective multicenter collaborative studies. Only in this way can more patients receive standardized treatment.

Current guidelines already provide treatment pathways based on low-, intermediate-, and high-risk categories. Looking ahead, we hope to advance further toward individualized care: treatment decisions should be tailored to each patient’s specific circumstances, incorporating early surgery, radiotherapy, and subsequent systemic therapies. The latter include targeted therapy, immunotherapy, and emerging approaches such as RNA tumor vaccines and cell therapies, including CAR-T. Together, these approaches can establish comprehensive, full-course management for renal cancer, making the disease treatable and enabling long-term disease control, so that patients can live longer and enjoy a better quality of life.